|Bid||1.89 x 2000|
|Ask||2.80 x 3700|
|Day's Range||2.43 - 2.71|
|52 Week Range||1.30 - 5.48|
|PE Ratio (TTM)||-4.88|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
SYDNEY , Oct. 18, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued ...
Categories: Yahoo FinanceGet free summary analysis Benitec Biopharma Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Benitec Biopharma Ltd. – Ionis Pharmaceuticals, Inc. and Affimed N.V. (IONS-US and AFMD-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.12 million, ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Benitec Biopharma Ltd. reports financial results for the year ended June 30, 2017. We analyze the earnings along side the following peers of Benitec Biopharma Ltd. – Oncolytics Biotech Inc., Medivir AB Unsponsored ADR and OpGen, Inc. (ONC-CA, MVRBY-US and OPGN-US) that have also reported for this period. Highlights Gross margins ... Read more (Read more...)
NASDAQ: BNTCW) is pleased to announce it has developed a new single vector (gene therapy construct) system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with oculopharyngeal muscular dystrophy (OPMD), while simultaneously adding back a copy of the normal version of the same gene to restore gene function. This next generation single vector system, termed BB-301, represents the clinical candidate that Benitec intends to advance into human clinical trials in the second half of calendar year 2018.
NEW YORK, NY / ACCESSWIRE / April 5, 2017 / On Tuesday, Benitec Biopharma and Paratek Pharmaceuticals both reported FDA trial results and investors moved quickly to take advantage of the good news. Volume ...
Paratek, Cyclacel and Benitec stocks led a biotech surge on Tuesday, rising on strong trial results.
NASDAQ: BNTCW) is pleased to announce that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications, an open access scientific journal published by the Nature Publishing Group. OPMD, a rare progressive muscle-wasting disease caused by mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene, is characterised by eyelid drooping, swallowing difficulties, and proximal limb weakness.
NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Higher volumes were the order of the day for these two biotech stocks, as each stock saw a double digit percent increase in the price of their stocks. Regulus ...
SYDNEY, March 13, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (Benitec) today announced that in accordance with the Share Subscription Agreement dated 24 October ...
SYDNEY, Feb. 16, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that it will present pivotal data from the Company's hepatitis B virus (HBV) in vivo ...
NEW YORK, NY / ACCESSWIRE / February 3, 2017 / The Biotech Industry has experienced some steep losses in recent years, but has begun to show some signs of stabilization in 2017. The Industry was home to ...
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
The results of this work will be presented by Dr David Suhy, Benitec's Chief Scientific Officer, at the Association for Research in Vision and Ophthalmology (ARVO)-Asia meeting being held in Brisbane on February 5th to February 8th, and the Translational Vision Summit (TVS), being held in conjunction. ARVO-Asia is a leading conference dedicated to eye and vision research in the Asia-Pacific region.
NASDAQ: BNTCW) is pleased to announce that it has initiated work on two new oncology pipeline programs after executing a Research Collaboration Agreement with Nant Capital LLC (Nant). This transaction represents a further step in establishing a strategic alliance with Nant around the development and funding of the head and neck cancer squamous cell carcinoma (HNSCC) programs. Greg West, CEO said, "We have hit the ground running in launching into the development of these two oncology programs.
NEW YORK, NY / ACCESSWIRE / January 18, 2017 / Biotech and Pharmaceutical companies took a hit last week after President Trump criticized the drug industry at a press conference. "We have to get our ...
Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.
Upcoming AWS Coverage on Biogen LONDON, UK / ACCESSWIRE / January 18, 2017 / Active Wall St. blog coverage looks at the headline from Benitec Biopharma Ltd (NASDAQ: BNTC ) as the Company announced on January ...
A few biotech and pharma companies were on the move Tuesday. A few of the smaller caps made tremendous gains on the day, as the fourth-quarter earnings season is kicking off.
SYDNEY, Jan. 17, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that the European Commission, based on a favourable recommendation from the ...
Opportunity Analysis and Forecast to 2024, February 2016), approximately 64,000 new patients will be diagnosed annually in the US with HNSCC and 50% of the patients are expected to develop recurrent or metastatic disease, with approximately 13,000 annual deaths expected in the US from HNSCC.
SYDNEY, Dec. 20, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced significant progress on use of the company's technology for development of a ddRNAi ...
NASDAQ: BNTCW) ("Benitec") announces that it has commenced a strategic engagement with NantVentures. NantVentures was founded by Dr. Patrick Soon-Shiong and serves as the private investment arm of NantWorks and California Capital. The strategic engagement includes an immediate placement to Nant Capital, LLC, an investment entity associated with NantVentures, of 29,305,819 fully paid ordinary shares in Benitec, representing 19.99% of its existing issued capital for a post-issue holding of 16.67%.